The Federal Trade Commission of America has imposed conditions on Sun Pharmaceuticalsâ€™ acquisition of Ranbaxy on the grounds that the USD 4 billion proposed deal would likely be anti-competitive.  To settle charges, Ranbaxy Laboratories have agreed to divest their interests in generic minocycline which will be acquired by Torrent Pharmaceuticals, a global drug company based in India.